Concepedia

Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy

James B. Brock, Peyton Herrington, Melissa Hickman, Aubri B. Hickman

Clinical Infectious Diseases · 2023 · 41 citations · 3 references

DOI

Concepts

Abstract

We report 12 patients with persistent viremia on oral antiretroviral therapy who were initiated on injectable cabotegravir/rilpivirine (iCAB/RPV) without oral lead-in. All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.

References

3

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

, , +15

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Chloe Orkin, Enrique Bernal, Darrell H. S. Tan et al. · The Lancet HIV · 2021 · 142 citations

, , +17

Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV

Monica Gandhi, Matthew D. Hickey, Elizabeth Imbert et al. · Annals of Internal Medicine · 2023 · 108 citations · Full text

, , +12